Matthew B. Klein
Director at ClearPoint Neuro, Inc. (CLPT); CEO at Ptc Therapeutics, Inc. (PTCT)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $4.4M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 6SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 10,292383,868 held (−3%) | $68.57 | $706K | -5.6% |
| May 26SEC | CLPTClearPoint Neuro, Inc. | Sell | 16,00046,935 held (−25%) | $11.59 | $185K | -9.6% |
| May 15SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 679405,891 held (−0%) | $73.06 | $50K | -11.4% |
| May 15SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 7,221398,670 held (−2%) | $73.08 | $528K | -11.5% |
| May 15SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 2,100396,570 held (−1%) | $73.08 | $153K | -11.5% |
| May 15SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 2,572393,998 held (−1%) | $72.46 | $186K | -10.7% |
| Apr 23SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 2,850394,070 held (−1%) | $70.91 | $202K | -8.8% |
| Mar 13SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 2,662396,920 held (−1%) | $64.08 | $171K | +1.0% |
| Feb 20SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 7,371387,082 held (−2%) | $69.36 | $511K | -6.7% |
| Jan 12SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 2,514394,453 held (−1%) | $76.45 | $192K | -15.4% |
| Jan 8SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 5,149399,983 held (−1%) | $76.95 | $396K | -15.9% |
| Jan 8SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 3,016396,967 held (−1%) | $77.48 | $234K | -16.5% |
| Jan 2SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 8,089341,875 held (−2%) | $76.64 | $620K | -15.6% |
| Dec 3SEC | PTCTPtc Therapeutics, Inc. | Sell Plan | 3,428349,964 held (−1%) | $79.07 | $271K | -18.2% |
- Sell
CEO Matthew B. Klein sold $706K of PTCT at $68.57 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Matthew B. Klein sold $185K of CLPT at $11.59 — cuts the stake by 25%.
- Sell
CEO Matthew B. Klein sold $50K of PTCT at $73.06 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Matthew B. Klein sold $528K of PTCT at $73.08 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Matthew B. Klein sold $153K of PTCT at $73.08 — pre-scheduled 10b5-1 plan sale.
- Sell
CEO Matthew B. Klein sold $186K of PTCT at $72.46 — pre-scheduled 10b5-1 plan sale.